Home › Funds › Merck & Co., Inc. › EIKN
Merck & Co., Inc. position in EIKN
EIKON THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 1,666,666 shares of EIKN (EIKON THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$13.4M, representing 1.63% of its reported portfolio and ranking #5 among its reported holdings. Merck & Co., Inc. has disclosed EIKN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s EIKN position evolved
Merck & Co., Inc. first disclosed a stake in EIKN in Q1 2026 at 1,666,666 shares (US$17.6M). The position peaked in Q2 2026 at 1,666,666 shares, worth US$21.7M. Across 3 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,666,666 shares valued at US$13.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.67M | $17.63M | New |
| Q2 2026 | 1.67M | $21.75M | Hold |
| Q3 2026 | 1.67M | $13.40M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EIKN and 13F data
EIKN (EIKON THERAPEUTICS INC) is a Health Care company. 97 other funds we track also report a position in EIKN — the largest reported positions include Foresite Capital Management IV, LLC (US$25.4M), Foresite Capital Management V, LLC (US$17.2M), EcoR1 Capital, LLC (US$9.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EIKN
- Foresite Capital Management IV, LLC 1.94M sh · $25.37M · Q2 2026
- Foresite Capital Management V, LLC 1.32M sh · $17.21M · Q2 2026
- EcoR1 Capital, LLC 732.61K sh · $9.56M · Q2 2026
- StepStone Group LP 395.34K sh · $5.16M · Q2 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 635.13K sh · $5.11M · Q3 2026
- General Catalyst Group Management, LLC 305.23K sh · $3.98M · Q2 2026
- SOROS CAPITAL MANAGEMENT LLC 484.67K sh · $3.90M · Q3 2026
- Comprehensive Financial Management LLC 116.28K sh · $1.52M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held EIKN?
Merck & Co., Inc. has disclosed EIKN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Merck & Co., Inc.'s current position in EIKN?
As of Q3 2026, Merck & Co., Inc. holds 1.67M shares of EIKN (EIKON THERAPEUTICS INC), valued at $13.40M, representing 1.63% of its reported portfolio and ranking #5.
Has Merck & Co., Inc. been buying or selling EIKN?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in EIKN. The position peaked in Q2 2026 at 1.67M shares.
Which other funds hold EIKN?
Other major institutional holders of EIKN include Foresite Capital Management IV, LLC, Foresite Capital Management V, LLC, EcoR1 Capital, LLC, among 97 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.